Clinical effects of prior anthracycline or taxane use on eribulin as first-line treatment for HER+/- locally recurrent or metastatic breast cancer (BC): Results from two phase II, multicenter, single-arm studies.

Authors

Stefan Gluck

Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL

Stefan Gluck , Joyce O'Shaughnessy , Kristi McIntyre , Lee Steven Schwartzberg , Sharon Wilks , Shannon Puhalla , Erhan Berrak , James Song , David Cox , Linda T. Vahdat

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2014 Breast Cancer Symposium

bookmark_border

Clinical effects of prior anthracycline or taxane use on eribulin as first-line treatment for HER+/- locally recurrent or metastatic breast cancer (BC): Results from 2 phase 2, multicenter, single-arm studies.

First Author: Stefan Gluck

insert_chart_outlined

Poster

2014 ASCO Annual Meeting

bookmark_border

Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for HER2+ locally recurrent or metastatic breast cancer (MBC): Results from a phase II, single-arm, multicenter study.

First Author: Shannon Puhalla

insert_chart_outlined

Poster

2011 ASCO Annual Meeting

bookmark_border

MARIANNE: A phase III, randomized study of trastuzumab-DM1 (T-DM1) with or without pertuzumab (P) compared with trastuzumab (H) plus taxane for first-line treatment of HER2-positive, progressive, or recurrent locally advanced or metastatic breast cancer (MBC).

First Author: P. A. Ellis

insert_chart_outlined

Poster

2024 ASCO Gastrointestinal Cancers Symposium

bookmark_border

HLX22 plus HLX02 and XELOX for first-line treatment of HER2-positive locally advanced or metastatic gastric/gastroesophageal junction cancer: A randomized, double-blind, multicenter phase 2 study.

First Author: Jin Li